Proteomics International Laboratories (ASX:PIQ) formed its clinical advisory board for PromarkerEso, a diagnostic blood test for esophageal cancer, according to a Monday filing with the Australian bourse.
The advisory board will provide guidance and clinical insights for the global commercialization of PromarkerEso, the filing said.
The company is set to launch PromarkerEso in Australia, with other jurisdictions expected to follow, per the filing.
Shares fell 8% in recent trade on Monday.